CORD-19:12d35c12218f230c49f4dc892814ba9f1037f251 / 61451-61674 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T55","span":{"begin":0,"end":223},"obj":"Sentence"}],"text":"To this end, toxicity trials in non-human primates have already demonstrated that agonistic OX40 antibody therapy is well tolerated and safe, therefore providing a strong rationale to pursue clinical tests in humans (168) ."}

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T22135","span":{"begin":0,"end":223},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To this end, toxicity trials in non-human primates have already demonstrated that agonistic OX40 antibody therapy is well tolerated and safe, therefore providing a strong rationale to pursue clinical tests in humans (168) ."}